drugset / Trial / NCT01515579
Comparison of Two Liraglutide Formulations in Healthy Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide at pH 8.15 (formulation 4) and liraglutide at pH 7.7 (formulation 3).
Timeline
- Start
- 2006-04
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 6 mg/ml | Subcutaneous |
| Subject | Liraglutide | Peptide | 6.25 mg/ml | Subcutaneous |